Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 192
Filter
1.
Pediatr Int ; 65(1): e15525, 2023.
Article in English | MEDLINE | ID: covidwho-20238288

ABSTRACT

BACKGROUND: The coronavirus disease 2019 outbreak has prompted some hospitals to implement screening tests upon admission since 2020. FilmArray® Respiratory 2.1 Panel (FilmArray) is a multiplex polymerase chain reaction (PCR) test with high sensitivity and specificity for detecting respiratory pathogens. We aimed to assess the clinical influence of the routine use of FilmArray for pediatric patients, including those without symptoms suggestive of an infection. METHODS: We conducted a single-center retrospective observational study, which investigated patients aged ≤15 years who underwent FilmArray on admission in 2021. We collected the patients' epidemiological information, symptoms, and FilmArray results from their electronic health records. RESULTS: A positive result was observed in 58.6% of patients admitted to the general ward or intensive care unit (ICU) but only in 1.5% of patients in the neonatal ward. Among the patients admitted to the general ward or ICU who tested positive, 93.3% had symptoms suggestive of infections, 44.6% had a sick contact before admission, and 70.5% had siblings. However, 62 (28.2%) out of 220 patients without the four (fever, respiratory, gastrointestinal, and dermal) symptoms also had positive results. Among them, 18 patients with adenovirus and three with respiratory syncytial virus were isolated to private rooms. However, 12 (57.1%) patients were discharged without symptoms suggestive of viral infection. CONCLUSION: Multiplex PCR routine use for all inpatients may lead to excessive management of positive cases because FilmArray cannot quantify microorganisms. Thus, targets for testing should be considered carefully based on patients' symptoms and histories of sick contacts.


Subject(s)
COVID-19 , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Virus Diseases , Infant, Newborn , Humans , Child , Multiplex Polymerase Chain Reaction/methods , Respiratory Tract Infections/diagnosis , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19 Testing
2.
J Infect Chemother ; 29(7): 678-682, 2023 Jul.
Article in English | MEDLINE | ID: covidwho-20237106

ABSTRACT

BACKGROUND: Parainfluenza virus type 3 (PIV-3) is one of the common pathogens for respiratory infections in children. Whether viral load of PIV-3 is associated with severity of respiratory diseases in children is not yet known. Our aim was to determine significance of PIV-3 viral load among infected children. METHODS: We conducted a single-center, retrospective study at Tokyo Metropolitan. Children's Medical Center, Japan, from June to August 2021. Hospitalized children were screened with a posterior nasal swab for multiplex PCR, and viral load was subsequently measured from remained samples by real-time PCR. Demographic data were collected from digital charts. PIV-3 positive patients were categorized into mild group with no oxygen demand, moderate group with low-flow oxygen demand and severe group with high-flow nasal cannula oxygen or non-invasive positive pressure ventilation or mechanical ventilation. Viral loads were compared among mild, moderate and severe groups. RESULTS: 151 patients were positive for PIV-3. We found no statistically significant association among PIV-3 viral load and severity of respiratory diseases (p = 0.35), and no statistically significant association between severity of illness and co-detection of other viruses. In each severity group, relatively high viral load per posterior nasal swab was observed at the time of testing. CONCLUSION: Among PIV-3 patients, we could not find statistically significant between viral load and their severity, therefore we could not conclude that viral load is a good surrogate marker for clinical severity of PIV-3.


Subject(s)
Respiratory Tract Infections , Virus Diseases , Child , Humans , Infant , Parainfluenza Virus 3, Human/genetics , Viral Load , Retrospective Studies , Respiratory Tract Infections/diagnosis , Multiplex Polymerase Chain Reaction
3.
Euro Surveill ; 28(23)2023 Jun.
Article in English | MEDLINE | ID: covidwho-20233468

ABSTRACT

BackgroundIn 2020, due to the COVID-19 pandemic, the European Centre for Disease Prevention and Control (ECDC) accelerated development of European-level severe acute respiratory infection (SARI) surveillance.AimWe aimed to establish SARI surveillance in one Irish hospital as part of a European network E-SARI-NET.MethodsWe used routine emergency department records to identify cases in one adult acute hospital. The SARI case definition was adapted from the ECDC clinical criteria for a possible COVID-19 case. Clinical data were collected using an online questionnaire. Cases were tested for SARS-CoV-2, influenza and respiratory syncytial virus (RSV), including whole genome sequencing (WGS) on SARS-CoV-2 RNA-positive samples and viral characterisation/sequencing on influenza RNA-positive samples. Descriptive analysis was conducted for SARI cases hospitalised between July 2021 and April 2022.ResultsOverall, we identified 437 SARI cases, the incidence ranged from two to 28 cases per week (0.7-9.2/100,000 hospital catchment population). Of 431 cases tested for SARS-CoV-2 RNA, 226 (52%) were positive. Of 349 (80%) cases tested for influenza and RSV RNA, 15 (4.3%) were positive for influenza and eight (2.3%) for RSV. Using WGS, we identified Delta- and Omicron-dominant periods. The resource-intensive nature of manual clinical data collection, specimen management and laboratory supply shortages for influenza and RSV testing were challenging.ConclusionWe successfully established SARI surveillance as part of E-SARI-NET. Expansion to additional sentinel sites is planned following formal evaluation of the existing system. SARI surveillance requires multidisciplinary collaboration, automated data collection where possible, and dedicated personnel resources, including for specimen management.


Subject(s)
COVID-19 , Influenza, Human , Pneumonia , Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Adult , Humans , Infant , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Ireland/epidemiology , Pandemics , RNA, Viral/genetics , Sentinel Surveillance , COVID-19/epidemiology , SARS-CoV-2/genetics , Hospitals , Pneumonia/epidemiology , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Syncytial Virus Infections/epidemiology
5.
Eur Rev Med Pharmacol Sci ; 27(8): 3777-3783, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2316118

ABSTRACT

OBJECTIVE: Respiratory viral diseases are common in children. A viral diagnostic test is necessary, because COVID-19 shows signs and symptoms similar to those of common respiratory viruses. The article aims at analyzing the presence of respiratory viruses that were common before the pandemic in children who were tested for suspected COVID-19, and is also concerned with how common respiratory viruses were impacted by COVID-19 measures during the second year of pandemic. PATIENTS AND METHODS: Nasopharyngeal swabs were examined to detect the presence of respiratory viruses. The respiratory panel kit included SARS-CoV-2, influenza A and B, rhinovirus/enterovirus, parainfluenza 1, 2, 3 and 4, coronaviruses NL 63, 229E, OC43, and HKU1, human metapneumovirus A/B, human bocavirus, respiratory syncytial virus (RSV) A/B, human parechovirus, and adenovirus. Virus scans were compared during and after the restricted period. RESULTS: No virus was isolated from the 86 patients. SARS-CoV-2 was the most frequently observed virus, as expected, and rhinovirus was the second, and coronavirus OC43 was the third. Influenza viruses and RSV were not detected in the scans. CONCLUSIONS: Influenza and RSV viruses disappeared during the pandemic period and rhinovirus was the second most common virus after the CoVs during and after the restriction period. Non-pharmaceutical interventions should be established as a precaution to prevent infectious diseases even after the pandemic.


Subject(s)
COVID-19 , Enterovirus Infections , Influenza, Human , Metapneumovirus , Orthomyxoviridae , Respiratory Tract Infections , Vaccines , Viruses , Humans , Child , Respiratory Syncytial Viruses , Influenza, Human/epidemiology , Pandemics , Respiratory Tract Infections/diagnosis , COVID-19/epidemiology , COVID-19/prevention & control , SARS-CoV-2 , Rhinovirus
6.
J Infect ; 86(5): 462-475, 2023 05.
Article in English | MEDLINE | ID: covidwho-2289420

ABSTRACT

OBJECTIVES: The clinical impact of rapid sample-to-answer "syndromic" multiplex polymerase chain reaction (PCR) testing for respiratory viruses is not clearly established. We performed a systematic literature review and meta-analysis to evaluate this impact for patients with possible acute respiratory tract infection in the hospital setting. METHODS: We searched EMBASE, MEDLINE, and Cochrane databases from 2012 to present and conference proceedings from 2021 for studies comparing clinical impact outcomes between multiplex PCR testing and standard testing. RESULTS: Twenty-seven studies with 17,321 patient encounters were included in this review. Rapid multiplex PCR testing was associated with a reduction of - 24.22 h (95% CI -28.70 to -19.74 h) in the time to results. Hospital length of stay was decreased by -0.82 days (95% CI -1.52 to -0.11 days). Among influenza positive patients, antivirals were more likely to be given (RR 1.25, 95% CI 1.06-1.48) and appropriate infection control facility use was more common with rapid multiplex PCR testing (RR 1.55, 95% CI 1.16-2.07). CONCLUSIONS: Our systematic review and meta-analysis demonstrates a reduction in time to results and length of stay for patients overall along with improvements in appropriate antiviral and infection control management among influenza-positive patients. This evidence supports the routine use of rapid sample-to-answer multiplex PCR testing for respiratory viruses in the hospital setting.


Subject(s)
Influenza, Human , Respiratory Tract Infections , Viruses , Humans , Influenza, Human/diagnosis , Influenza, Human/drug therapy , Multiplex Polymerase Chain Reaction/methods , Viruses/genetics , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/drug therapy , Antiviral Agents/therapeutic use
7.
Acta Paediatr ; 112(5): 1049-1055, 2023 05.
Article in English | MEDLINE | ID: covidwho-2301196

ABSTRACT

AIM: Human bocavirus 1 (HBoV1) has been associated with respiratory tract infections in children. We aimed at retrospectively describing patient characteristics, seasonality, pre-existing medical conditions, codetections, clinical manifestations and complications of HBoV1 infection in relation to viral load in the child population in Stockholm, with the overarching aim of elucidating the clinical significance of HBoV1. METHODS: We included all hospitalised children 0-17 years testing positive for HBoV1 by real-time polymerase chain reaction on nasopharyngeal aspirates 1 July 2008-30 June 2019. Patients with HBoV1 single detection, high viral load expressed as an HBoV1-DNA cycle threshold (Ct) < 25, or both, were separately analysed. We retrieved information on pre-existing conditions and clinical course from the medical records. RESULTS: We found 768 episodes in 727 children, 496 (64.6%) male and 441 (60.7%) previously healthy. The median age was 17.6 months. Most (476/768, 62.0%) episodes occurred during December-March. HBoV1 was in 549 episodes (71.5%) codetected with other viruses. Ct < 25 was independently associated with young age, single detection of HBoV1 and presentation early in the epidemic season. We saw few differences in clinical manifestations between the subgroups. CONCLUSION: Our findings are consistent with primary HBoV1 infection causing mild-to-severe respiratory tract manifestations in young children.


Subject(s)
Human bocavirus , Parvoviridae Infections , Respiratory Tract Infections , Humans , Child , Male , Infant , Child, Preschool , Female , Human bocavirus/genetics , Retrospective Studies , Parvoviridae Infections/diagnosis , Parvoviridae Infections/epidemiology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Real-Time Polymerase Chain Reaction
8.
BMC Pulm Med ; 23(1): 111, 2023 Apr 06.
Article in English | MEDLINE | ID: covidwho-2300637

ABSTRACT

BACKGROUND: Eosinophilic airway inflammation caused by respiratory virus infection has been demonstrated in basic research; however, clinical investigations are lacking. To clarify the extent to which respiratory virus infection induces airway eosinophilic inflammation, we reviewed the results of bronchoalveolar lavage (BAL) and respiratory virus testing performed at our hospital. METHODS: Among the BAL procedures performed at the University of the Ryukyu Hospital from August 2012 to September 2016, we collected cases of acute respiratory disease in which multiplex polymerase chain reaction (PCR) was used to search for respiratory viruses. The effect of respiratory virus detection on BAL eosinophil fraction was analyzed using statistical analysis. A case study was conducted on respiratory virus detection, which showed an elevated BAL eosinophil fraction. RESULTS: A total of 95 cases were included in this study, of which 17 were PCR-positive. The most common respiratory virus detected was parainfluenza virus (eight cases). The PCR-positive group showed a higher BAL eosinophil fraction than the PCR-negative group (p = 0.030), and more cases had a BAL eosinophil fraction > 3% (p = 0.017). Multivariate analysis revealed that being PCR-positive was significantly associated with BAL eosinophil fraction > 1% and > 3%. There were nine PCR-positive cases with a BAL eosinophil fraction > 1%, of which two cases with parainfluenza virus infection had a marked elevation of BAL eosinophil fraction and were diagnosed with eosinophilic pneumonia. CONCLUSIONS: Cases of viral infection of the lower respiratory tract showed an elevated BAL eosinophil fraction. The increase in eosinophil fraction due to respiratory virus infection was generally mild, whereas some cases showed marked elevation and were diagnosed with eosinophilic pneumonia. Respiratory virus infection is not a rare cause of elevated BAL eosinophil fraction and should be listed as a differential disease in the practice of eosinophilic pneumonia.


Subject(s)
Pulmonary Eosinophilia , Respiratory Tract Infections , Virus Diseases , Viruses , Humans , Bronchoalveolar Lavage , Bronchoalveolar Lavage Fluid , Eosinophils , Inflammation , Pulmonary Eosinophilia/diagnosis , Respiratory Tract Infections/diagnosis , Retrospective Studies , Virus Diseases/diagnosis
9.
N Engl J Med ; 388(16): 1465-1477, 2023 Apr 20.
Article in English | MEDLINE | ID: covidwho-2305422

ABSTRACT

BACKGROUND: Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown. METHODS: In this ongoing, phase 3 trial, we randomly assigned, in a 1:1 ratio, adults (≥60 years of age) to receive a single intramuscular injection of RSVpreF vaccine at a dose of 120 µg (RSV subgroups A and B, 60 µg each) or placebo. The two primary end points were vaccine efficacy against seasonal RSV-associated lower respiratory tract illness with at least two or at least three signs or symptoms. The secondary end point was vaccine efficacy against RSV-associated acute respiratory illness. RESULTS: At the interim analysis (data-cutoff date, July 14, 2022), 34,284 participants had received RSVpreF vaccine (17,215 participants) or placebo (17,069 participants). RSV-associated lower respiratory tract illness with at least two signs or symptoms occurred in 11 participants in the vaccine group (1.19 cases per 1000 person-years of observation) and 33 participants in the placebo group (3.58 cases per 1000 person-years of observation) (vaccine efficacy, 66.7%; 96.66% confidence interval [CI], 28.8 to 85.8); 2 cases (0.22 cases per 1000 person-years of observation) and 14 cases (1.52 cases per 1000 person-years of observation), respectively, occurred with at least three signs or symptoms (vaccine efficacy, 85.7%; 96.66% CI, 32.0 to 98.7). RSV-associated acute respiratory illness occurred in 22 participants in the vaccine group (2.38 cases per 1000 person-years of observation) and 58 participants in the placebo group (6.30 cases per 1000 person-years of observation) (vaccine efficacy, 62.1%; 95% CI, 37.1 to 77.9). The incidence of local reactions was higher with vaccine (12%) than with placebo (7%); the incidences of systemic events were similar (27% and 26%, respectively). Similar rates of adverse events through 1 month after injection were reported (vaccine, 9.0%; placebo, 8.5%), with 1.4% and 1.0%, respectively, considered by the investigators to be injection-related. Severe or life-threatening adverse events were reported in 0.5% of vaccine recipients and 0.4% of placebo recipients. Serious adverse events were reported in 2.3% of participants in each group through the data-cutoff date. CONCLUSIONS: RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (≥60 years of age), without evident safety concerns. (Funded by Pfizer; RENOIR ClinicalTrials.gov number, NCT05035212; EudraCT number, 2021-003693-31.).


Subject(s)
Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus Vaccines , Respiratory Tract Infections , Aged , Humans , Antibodies, Viral , Double-Blind Method , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Vaccines/administration & dosage , Respiratory Syncytial Virus Vaccines/adverse effects , Respiratory Syncytial Virus Vaccines/therapeutic use , Vaccines, Combined/administration & dosage , Vaccines, Combined/adverse effects , Vaccines, Combined/therapeutic use , Vaccine Efficacy , Treatment Outcome , Middle Aged , Injections, Intramuscular , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/prevention & control
10.
PeerJ ; 11: e15008, 2023.
Article in English | MEDLINE | ID: covidwho-2303066

ABSTRACT

Background: The epidemiology of respiratory tract infections (RTI) has dramatically changed over the course of the COVID-19 pandemic. A major effort in the clinical management of RTI has been directed toward diagnosing COVID-19, while the causes of other, common community RTI often remain enigmatic. To shed light on the etiological causes of RTI during a low COVID-19 transmission period in 2021, we did a pilot study using molecular testing for virologic causes of upper RTI among adults with respiratory symptoms from Almaty, Kazakhstan. Methods: Adults presenting at two public hospitals with respiratory symptoms were screened using SARS-CoV-2 PCR on nasopharyngeal swabs. A subset of RTI+, COVID-19-negative adults (n = 50) was then tested for the presence of common RTI viruses and influenza A virus (IAV). Next generation virome sequencing was used to further characterize the PCR-detected RTI pathogens. Results: Of 1,812 symptomatic adults, 21 (1.2%) tested SARS-CoV-2-positive. Within the COVID-19 negative outpatient subset, 33/50 subjects (66%) had a positive PCR result for a common community RTI virus, consisting of human parainfluenza virus 3-4 (hPIV 3-4) in 25/50 (50%), rhinovirus (hRV) in 2 (4%), hPIV4-hRV co-infection in four (8%) and adenovirus or the OCR43/HKU-1 coronavirus in two (4%) cases; no IAV was detected. Virome sequencing allowed to reconstruct sequences of most PCR-identified rhinoviruses and hPIV-3/human respirovirus-3. Conclusions: COVID-19 was cause to a low proportion of symptomatic RTI among adults. Among COVID-negative participants, symptomatic RTI was predominantly associated with hPIV and hRV. Therefore, respiratory viruses other than SARS-CoV-2 should be considered in the clinical management and prevention of adult RTI in the post-pandemic era.


Subject(s)
COVID-19 , Influenza A virus , Respiratory Tract Infections , Adult , Humans , COVID-19/epidemiology , Pandemics , Pilot Projects , SARS-CoV-2/genetics , Respiratory Tract Infections/diagnosis , Parainfluenza Virus 1, Human , Rhinovirus/genetics , Parainfluenza Virus 2, Human , Multiplex Polymerase Chain Reaction
11.
BMJ Open ; 13(4): e067878, 2023 04 21.
Article in English | MEDLINE | ID: covidwho-2302319

ABSTRACT

OBJECTIVES: To systematically review and evaluate diagnostic models used to predict viral acute respiratory infections (ARIs) in children. DESIGN: Systematic review. DATA SOURCES: PubMed and Embase were searched from 1 January 1975 to 3 February 2022. ELIGIBILITY CRITERIA: We included diagnostic models predicting viral ARIs in children (<18 years) who sought medical attention from a healthcare setting and were written in English. Prediction model studies specific to SARS-CoV-2, COVID-19 or multisystem inflammatory syndrome in children were excluded. DATA EXTRACTION AND SYNTHESIS: Study screening, data extraction and quality assessment were performed by two independent reviewers. Study characteristics, including population, methods and results, were extracted and evaluated for bias and applicability using the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies and PROBAST (Prediction model Risk Of Bias Assessment Tool). RESULTS: Of 7049 unique studies screened, 196 underwent full text review and 18 were included. The most common outcome was viral-specific influenza (n=7; 58%). Internal validation was performed in 8 studies (44%), 10 studies (56%) reported discrimination measures, 4 studies (22%) reported calibration measures and none performed external validation. According to PROBAST, a high risk of bias was identified in the analytic aspects in all studies. However, the existing studies had minimal bias concerns related to the study populations, inclusion and modelling of predictors, and outcome ascertainment. CONCLUSIONS: Diagnostic prediction can aid clinicians in aetiological diagnoses of viral ARIs. External validation should be performed on rigorously internally validated models with populations intended for model application. PROSPERO REGISTRATION NUMBER: CRD42022308917.


Subject(s)
COVID-19 , Respiratory Tract Infections , Virus Diseases , Child , Humans , Bias , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19 Testing , Prognosis , Respiratory Tract Infections/diagnosis , SARS-CoV-2 , Virus Diseases/diagnosis
12.
Sci Rep ; 13(1): 6319, 2023 04 18.
Article in English | MEDLINE | ID: covidwho-2306418

ABSTRACT

Respiratory tract infection is one of the most common reasons for both morbidity and mortality worldwide. High attention has been paid to the etiological tracing of respiratory tract infection since the advent of COVID-19. In this study, we aimed to evaluate the epidemiological features of pathogens in respiratory tract infection, especially during COVID-19 pandemic. A total of 7668 patients with respiratory tract infection who admitted to Qilu Hospital of Shandong University from March 2019 to Dec 2021 were retrospectively included. The respiratory tract specimens were detected using a commercial multiplex PCR-based panel assay for common respiratory pathogens including influenza A virus (Flu-A), influenza A virus H1N1 (H1N1), influenza A virus H3N2 (H3N2), influenza B virus (Flu-B), parainfluenza virus (PIV), respiratory syncytial virus (RSV), adenovirus (ADV), Boca virus (Boca), human Rhinovirus (HRV), Metapneumovirus (MPV), Coronavirus (COV), Mycoplasma pneumoniae (MP), and Chlamydia (Ch). The positive rates were compared using a chi-square test. Compared with 2019, the positive rate of pathogen detection during from January 2020 to December 2021 was significantly lower, especially the detection of Flu-A. The positive rate of respiratory pathogen strains was 40.18% during COVID-19 pandemic, and a total of 297 cases (4.69%) of mixed infection with two or more pathogens were detected. There was no statistical difference in the positive rate between male and female patients. However, the positive rates of infection were different among different age groups, with higher incidence of RSV in infancy and toddler group, and MP infection in children and teenager group. While, HRV was the most common pathogen in the adult patients. Moreover, Flu-A and Flu-B were higher in winter, and MP and RSV were higher in spring, autumn and winter. The pathogens such as ADV, BOCA, PIV, and COV were detected without significant seasonal distribution. In conclusion, respiratory pathogen infection rates may vary by age and season, regardless of gender. During the COVID-19 epidemic, blocking transmission routes could help reduce the incidence of respiratory tract infection. The current prevalence of respiratory tract infection pathogens is of great significance for clinical prevention, diagnosis and treatment.


Subject(s)
COVID-19 , Influenza A Virus, H1N1 Subtype , Influenza, Human , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Adult , Adolescent , Humans , Male , Female , Infant , COVID-19/epidemiology , Influenza A Virus, H3N2 Subtype , Pandemics , Retrospective Studies , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Influenza, Human/epidemiology , China/epidemiology , Multiplex Polymerase Chain Reaction , Mycoplasma pneumoniae , Parainfluenza Virus 1, Human
13.
Clin Infect Dis ; 75(6): 987-995, 2022 Sep 29.
Article in English | MEDLINE | ID: covidwho-2304216

ABSTRACT

BACKGROUND: Acute respiratory infections (ARI) are the most common infectious diseases globally. Community surveillance may provide a more comprehensive picture of disease burden than medically attended illness alone. METHODS: In this longitudinal study conducted from 2012 to 2017 in the Washington Heights/Inwood area of New York City, we enrolled 405 households with 1915 individuals. Households were sent research text messages twice weekly inquiring about ARI symptoms. Research staff confirmed symptoms by follow-up call. If ≥2 criteria for ARI were met (fever/feverish, cough, congestion, pharyngitis, myalgias), staff obtained a mid-turbinate nasal swab in participants' homes. Swabs were tested using the FilmArray reverse transcription polymerase chain reaction (RT-PCR) respiratory panel. RESULTS: Among participants, 43.9% were children, and 12.8% had a chronic respiratory condition. During the 5 years, 114 724 text messages were sent; the average response rate was 78.8% ± 6.8%. Swabs were collected for 91.4% (2756/3016) of confirmed ARI; 58.7% had a pathogen detected. Rhino/enteroviruses (51.9%), human coronaviruses (13.9%), and influenza (13.2%) were most commonly detected. The overall incidence was 0.62 ARI/person-year, highest (1.73) in <2 year-olds and lowest (0.46) in 18-49 year-olds. Approximately one-fourth of those with ARI sought healthcare; percents differed by pathogen, demographic factors, and presence of a chronic respiratory condition. CONCLUSIONS: Text messaging is a novel method for community-based surveillance that could be used both seasonally as well as during outbreaks, epidemics and pandemics. The importance of community surveillance to accurately estimate disease burden is underscored by the findings of low rates of care-seeking that varied by demographic factors and pathogens.


Subject(s)
Influenza, Human , Pharyngitis , Respiratory Tract Infections , Text Messaging , Child , Fever/epidemiology , Humans , Infant , Influenza, Human/epidemiology , Longitudinal Studies , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology
14.
Arch. argent. pediatr ; 120(4): 264-268, Agosto 2022. tab, ilus
Article in English, Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-2268490

ABSTRACT

Introducción. Durante el 2020, la circulación de otros virus respiratorios fue inferior a lo acostumbrado. Es probable que, almodificarse las medidas de mitigación para la infección por el coronavirus 2019, dicha prevalencia haya aumentado en 2021. Objetivo. Estimar la prevalencia de virus respiratorioshabituales en pacientes de 0 a 5 años asistidos en Departamento de Urgencias de un hospital pediátrico de la Ciudad Autónoma de Buenos Aires. Métodos. Estudio transversal con 348 pacientes que consultaronpor sospecha de enfermedad por el coronavirus 2019(COVID-19), en quienes se descartó dicha enfermedad y se realizó la pesquisa sistemática de virus respiratorios habitualesResultados. En el 40 % de los pacientes se identificó el virus sincicial respiratorio (VSR), un virus respiratorio habitual. La edad menor de 2 años se mostró como predictor independiente de VSR (razón de momios [OR]: 4,15; intervalos de confianza del 95 % [IC95 %]: 2,46-6,99). Conclusión. En la población estudiada, 40 % de los pacientes con sospecha de COVID-19 en quienes se descartó infección por SARS-CoV-2 presentaban infección por VSR.


Introduction. During 2020, circulation of other respiratory viruses was lower than usual. Most likely, as mitigation measures for coronavirus disease 2019 (COVID-19) were modified, their prevalence in 2021 may have increased. Objective. To estimate the prevalence of common respiratory viruses among patients aged 0­5 years seen at the Emergency Department of a children's hospital in the City of Buenos Aires. Methods. Cross-sectional study of 348 patients consulting for suspected COVID-19 in whom SARS-CoV-2 infection was ruled out and routine screening for common respiratory viruses was performed. Results. Respiratory syncytial virus (RSV), a common respiratory virus, was identified in 40% of patients. Age younger than 2 years was an independent predictor of RSV (odds ratio [OR]: 4.15; 95% confidence interval [CI]: 2.46­6.99). Conclusion. In the study population, 40% of patients suspected of COVID-19 in whom SARS-CoV-2 infection was ruled out had RSV infection.


Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Viruses , Respiratory Syncytial Virus, Human , COVID-19/diagnosis , COVID-19/epidemiology , Outpatients , Cross-Sectional Studies , Pandemics , SARS-CoV-2
15.
J Med Virol ; 95(4): e28688, 2023 04.
Article in English | MEDLINE | ID: covidwho-2256021

ABSTRACT

Viral metagenomics has been extensively applied for the identification of emerging or poorly characterized viruses. In this study, we applied metagenomics for the identification of viral infections among pediatric patients with acute respiratory disease, but who tested negative for SARS-CoV-2. Twelve pools composed of eight nasopharyngeal specimens were submitted to viral metagenomics. Surprisingly, in two of the pools, we identified reads belonging to the poorly characterized Malawi polyomavirus (MWPyV). Then, the samples composing the positive pools were individually tested using quantitative polymerase chain reaction for identification of the MWPyV index cases. MWPyV-positive samples were also submitted to respiratory virus panel testing due to the metagenomic identification of different clinically important viruses. Of note, MWPyV-positive samples tested also positive for respiratory syncytial virus types A and B. In this study, we retrieved two complete MWPyV genome sequences from the index samples that were submitted to phylogenetic inference to investigate their viral origin. Our study represents the first molecular and genomic characterization of MWPyV obtained from pediatric patients in South America. The detection of MWPyV in acutely infected infants suggests that this virus might participate (coparticipate) in cases of respiratory symptoms. Nevertheless, future studies based on testing of a larger number of clinical samples and MWPyV complete genomes appear to be necessary to elucidate if this emerging polyomavirus might be clinically important.


Subject(s)
COVID-19 , Polyomavirus Infections , Polyomavirus , Respiratory Tract Infections , Viruses , Infant , Child , Humans , Metagenomics , Brazil/epidemiology , Malawi/epidemiology , Phylogeny , SARS-CoV-2 , Polyomavirus Infections/epidemiology , Polyomavirus/genetics , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology
16.
Pediatr Infect Dis J ; 42(2): e52-e53, 2023 02 01.
Article in English | MEDLINE | ID: covidwho-2282233

ABSTRACT

The epidemiology and clinical manifestations of human metapneumovirus are not well studied in infants younger than 60 days of age. In this retrospective review of infants admitted for sepsis evaluation, we identified HMPV less frequently than other viral etiologies via nasopharyngeal multiplex polymerase chain reaction testing; in only 16 (1.9%) infants. Two infants had apneic episodes, but none had wheezing.


Subject(s)
Metapneumovirus , Paramyxoviridae Infections , Sepsis , Humans , Infant , Hospitalization/statistics & numerical data , Metapneumovirus/genetics , Metapneumovirus/isolation & purification , Nasopharynx , Paramyxoviridae Infections/diagnosis , Paramyxoviridae Infections/epidemiology , Paramyxoviridae Infections/virology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Reverse Transcriptase Polymerase Chain Reaction , Sepsis/diagnosis , Sepsis/epidemiology , Sepsis/etiology , Sepsis/virology , Age Factors
17.
J Integr Complement Med ; 29(3): 181-195, 2023 Mar.
Article in English | MEDLINE | ID: covidwho-2282076

ABSTRACT

Objective: Both the United Nations and the World Health Organization have identified antimicrobial resistance as a significant threat to global health. The Centers for Disease Control and Prevention identified five pediatric respiratory conditions as requiring particular scrutiny in terms of antibiotic stewardship. This study sought to identify strategies used by experienced naturopathic practitioners to treat acute respiratory infections in children. The authors theorize that naturopathic strategies safely fill the gap between watchful waiting and antibiotic prescription, thus reducing the use of antibiotics. Methods: Naturopathic practitioners in Canada, the United States, and Australia with a minimum of 5 years of experience in clinical naturopathic care of children were recruited for a modified Delphi study. A 14-person panel of practitioners was selected to complete a series of four iterative surveys assessing agreement to statements in five domains of knowledge/attitudes, assessment/diagnosis, management, monitoring, and education. Items were deemed to have reached consensus if they reached a predetermined threshold of 70% agreement, or failed to reach a threshold of 40% agreement. Items between these boundaries were modified and retested until either consensus was reached or the four surveys had been completed. Results: Results yielded a large degree of agreement on core naturopathic approaches to the management of acute pediatric respiratory infections, especially lifestyle strategies, including adequate rest and dietary recommendations. The use of vitamins C and D was strongly supported, as were herbs, particularly echinacea and elderberry. Some hydrotherapy and topical applications specific to the individual focus on infection also reached consensus. Results suggested that most respondents, even if they have the authority to prescribe antibiotics, rarely deem it necessary to do so. Conclusion: Findings of this study provide (1) clarity on the role of naturopathic doctors in the management of pediatric health concerns and the stewardship of antibiotics; and (2) initial guidance to less experienced naturopathic practitioners. The findings also identify key priorities for research into the safety and effectiveness of naturopathic interventions to reduce the unnecessary prescribing of antibiotics.


Subject(s)
Naturopathy , Respiratory Tract Infections , Humans , Child , United States , Delphi Technique , Naturopathy/methods , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Surveys and Questionnaires
18.
Ital J Pediatr ; 49(1): 40, 2023 Mar 29.
Article in English | MEDLINE | ID: covidwho-2272759

ABSTRACT

Rates of antibiotic-resistant bacteria have increased worldwide over recent years, but the Italian Institute of Health reported a disruption to this trend in 2021 compared with 2020. Children are often recipients of unnecessary antibiotic prescriptions, especially for respiratory tract infections (RTIs). During the initial phase of the COVID-19 pandemic, common RTIs substantially decreased, so it is conceivable that antibiotic prescriptions also reduced during this time. To test this hypothesis, we retrospectively collected data on all visits to a pediatric primary care clinic in Northern Italy from February 20, 2020 to June 2, 2020 and compared data with the same period in 2019. We evaluated the antibiotic prescription rate according to the diagnosis at discharge. While the total number of visits significantly decreased (1335 in 2020 vs. 4899 in 2019), there was only a slight reduction in the antibiotic prescription rate (1039 in 2019, 21.2%, vs. 272 in 2020, 20.4%). However, this corresponded to a 73.8% decrease in the total number of antibiotic prescriptions, with antibiotics for RTI accounting for 69% of the total reduction. It is possible that, at the larger scale, reduced antibiotic prescription in pediatrics during the COVID-19 pandemic resulted in a slight reduction in antimicrobial resistance.


Subject(s)
COVID-19 , Respiratory Tract Infections , Child , Humans , Anti-Bacterial Agents/therapeutic use , Drug Prescriptions , Retrospective Studies , Pandemics , COVID-19/epidemiology , Drug Resistance, Bacterial , Italy/epidemiology , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/diagnosis , Patient Discharge , Practice Patterns, Physicians'
19.
Am J Emerg Med ; 66: 146-151, 2023 04.
Article in English | MEDLINE | ID: covidwho-2249573

ABSTRACT

INTRODUCTION: Acute respiratory infections make up a sizable percentage of emergency department (ED) visits and many result in antibiotics being prescribed. Procalcitonin (PCT) has been found to reduce antibiotic use in both outpatient and critical care settings, yet remains underused in the ED. This study aimed to evaluate whether point of care molecular influenza and Respiratory Syncytial Virus (RSV) testing, PCT, and a pharmacist driven educational intervention in aggregate optimizes antibiotic and antiviral prescribing in the ED setting. METHODS: A randomized trial of the Cobas Liat Flu/RSV Assay, procalcitonin, and the use of pharmacist-led education in patients 0-50 years of age being seen in the ED for Influenza Like Illness (ILI) or acute respiratory illness. The study enrolled 200 ED patients between March 2018 and April 2022. RESULTS: There was little difference in antibiotic or antiviral prescribing between the intervention and control groups in this study (39%-32% = 7.0%, 95% CI: -6.2, 20.2, P = 0.30). However, a post-hoc analysis of the use of procalcitonin showed results were used as indicated in the ED (P = 0.001). CONCLUSION: PCT can be used in both adult and pediatric populations to help guide the decision of whether to treat with antibiotics in the ED setting. Pharmacist guided education may not be a driving factor.


Subject(s)
Influenza, Human , Respiratory Tract Infections , Adult , Child , Humans , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Influenza, Human/drug therapy , Pharmacists , Procalcitonin , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/drug therapy
20.
Arch Virol ; 168(3): 87, 2023 Feb 14.
Article in English | MEDLINE | ID: covidwho-2244493

ABSTRACT

A methodological approach based on reverse transcription (RT)-multiplex PCR followed by next-generation sequencing (NGS) was implemented to identify multiple respiratory RNA viruses simultaneously. A convenience sampling from respiratory surveillance and SARS-CoV-2 diagnosis in 2020 and 2021 in Montevideo, Uruguay, was analyzed. The results revealed the cocirculation of SARS-CoV-2 with human rhinovirus (hRV) A, B and C, human respiratory syncytial virus (hRSV) B, influenza A virus, and metapneumovirus B1. SARS-CoV-2 coinfections with hRV or hRSV B and influenza A virus coinfections with hRV C were identified in adults and/or children. This methodology combines the benefits of multiplex genomic amplification with the sensitivity and information provided by NGS. An advantage is that additional viral targets can be incorporated, making it a helpful tool to investigate the cocirculation and coinfections of respiratory viruses in pandemic and post-pandemic contexts.


Subject(s)
COVID-19 , Coinfection , Influenza A virus , Influenza, Human , RNA Viruses , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Child , Adult , Humans , COVID-19/diagnosis , COVID-19/epidemiology , Pandemics , RNA , COVID-19 Testing , Coinfection/diagnosis , Coinfection/epidemiology , SARS-CoV-2/genetics , RNA Viruses/genetics , Respiratory Syncytial Virus, Human/genetics , Influenza A virus/genetics , High-Throughput Nucleotide Sequencing , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Influenza, Human/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL